{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:52:07Z","timestamp":1791341527148,"version":"4.3.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002412","name":"Xi'an Jiaotong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007128","name":"Shaanxi Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Shaanxi Province Key Research and Development Projects","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.canlet.2026.218843","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:42:00Z","timestamp":1789800120000},"page":"218843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tumor-cell HMGB1 restrains CD8+ T-cell immunity during conventional fractionated radiotherapy"],"prefix":"10.1016","volume":"660","author":[{"given":"Chen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihai","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutiantian","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6887-3659","authenticated-orcid":false,"given":"Mengdi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingge","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8274-027X","authenticated-orcid":false,"given":"Yuzhu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4448-7725","authenticated-orcid":false,"given":"Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.canlet.2026.218843_bib1","doi-asserted-by":"crossref","first-page":"e1945","DOI":"10.1016\/S2214-109X(24)00355-3","article-title":"Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: a population-based study","volume":"12","author":"Zhu","year":"2024","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.canlet.2026.218843_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-3-030-38862-1_10","article-title":"Immunogenic cell death driven by radiation-impact on the tumor microenvironment","volume":"180","author":"Yamazaki","year":"2020","journal-title":"Cancer Treat Res."},{"issue":"8","key":"10.1016\/j.canlet.2026.218843_bib3","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2026.218843_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.canlet.2026.218843_bib5","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/jnci\/djad118","article-title":"Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations","volume":"115","author":"Karapetyan","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.canlet.2026.218843_bib6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/jamaoncol.2024.1527","article-title":"Radiation with immunotherapy may be a double-edged sword-how can we learn from recent negative clinical trials?","volume":"10","author":"McGee","year":"2024","journal-title":"JAMA Oncol."},{"issue":"30","key":"10.1016\/j.canlet.2026.218843_bib7","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218843_bib8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bpg.2016.07.003","article-title":"Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies","volume":"30","author":"Adebahr","year":"2016","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218843_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-06909-7","article-title":"Single-dose radiotherapy is more effective than fractionation when combined with anti-PD-1 immunotherapy in glioblastoma","volume":"15","author":"Cocito","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.canlet.2026.218843_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/s12885-024-12313-7","article-title":"Radiation-induced upregulation of FGL1 promotes esophageal squamous cell carcinoma metastasis via IMPDH1","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2026.218843_bib11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41590-019-0561-4","article-title":"Immunological impact of cell death signaling driven by radiation on the tumor microenvironment","volume":"21","author":"Rodriguez-Ruiz","year":"2020","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218843_bib12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.canlet.2026.218843_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-020-00940-z","article-title":"SBRT combined with PD-1\/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges","volume":"13","author":"Chen","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.canlet.2026.218843_bib14","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ab1c2b","article-title":"Dosimetric impact of esophagus motion in single fraction spine stereotactic body radiotherapy","volume":"64","author":"Wang","year":"2019","journal-title":"Phys. Med. Biol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218843_bib15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00066-020-01603-1","article-title":"Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO\/DGMP working group stereotactic radiotherapy and radiosurgery","volume":"196","author":"Guckenberger","year":"2020","journal-title":"Strahlenther. Onkol."},{"issue":"12","key":"10.1016\/j.canlet.2026.218843_bib16","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41577-023-00894-6","article-title":"The multifunctional protein HMGB1: 50 years of discovery","volume":"23","author":"Tang","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218843_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.intimp.2018.01.013","article-title":"HMGB1 silencing in macrophages prevented their functional skewing and ameliorated EAM development: nuclear HMGB1 may be a checkpoint molecule of macrophage reprogramming","volume":"56","author":"Jiang","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218843_bib18","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20209760","article-title":"HMGB1 coordinates SASP-related chromatin folding and RNA homeostasis on the path to senescence","volume":"17","author":"Sofiadis","year":"2021","journal-title":"Mol. Syst. Biol."},{"issue":"8","key":"10.1016\/j.canlet.2026.218843_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114591","article-title":"Nuclear HMGB1 is critical for CD8 T cell IFN-gamma production and anti-tumor immunity","volume":"43","author":"Xu","year":"2024","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.canlet.2026.218843_bib20","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/1541-7786.MCR-18-1025","article-title":"O-GlcNAcylation enhances double-strand break repair, promotes cancer cell proliferation, and prevents therapy-induced senescence in irradiated tumors","volume":"17","author":"Efimova","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218843_bib21","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1038\/s41467-024-51242-8","article-title":"PD-L1 deglycosylation promotes its nuclear translocation and accelerates DNA double-strand-break repair in cancer","volume":"15","author":"Shu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218843_bib22","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2026.218843_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12929-020-00670-x","article-title":"The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis","volume":"27","author":"Wang","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.canlet.2026.218843_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-70858-6","article-title":"CXCR5(+) monocyte emigration impairs the radiation-induced antitumor immune response","volume":"17","author":"Lei","year":"2026","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.canlet.2026.218843_bib25","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20232101","article-title":"Radiotherapy and immunology","volume":"221","author":"Wang","year":"2024","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.canlet.2026.218843_bib26","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.ccell.2024.11.002","article-title":"Myeloid effector cells in cancer","volume":"42","author":"Schol","year":"2024","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.canlet.2026.218843_bib27","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1158\/0008-5472.CAN-09-4672","article-title":"Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes","volume":"70","author":"Movahedi","year":"2010","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2026.218843_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semcancer.2003.10.009","article-title":"CCL2 (monocyte chemoattractant protein-1) and cancer","volume":"14","author":"Conti","year":"2004","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218843_bib29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","article-title":"Chemokines and the immune response to cancer","volume":"54","author":"Ozga","year":"2021","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.canlet.2026.218843_bib30","article-title":"Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies","volume":"1880","author":"Granica","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2026.218843_bib31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semcancer.2021.04.002","article-title":"Post-translational regulations of PD-L1 and PD-1: mechanisms and opportunities for combined immunotherapy","volume":"85","author":"Dai","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218843_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130362","article-title":"Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy","volume":"5","author":"Farren","year":"2020","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.canlet.2026.218843_bib33","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2014.08.008","article-title":"Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy","volume":"90","author":"Modh","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.canlet.2026.218843_bib34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2217\/fon-2018-0405","article-title":"JAVELIN head and neck 100: a phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer","volume":"15","author":"Yu","year":"2019","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218843_bib35","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial","volume":"25","author":"Machiels","year":"2024","journal-title":"Lancet Oncol."},{"issue":"33","key":"10.1016\/j.canlet.2026.218843_bib36","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"6894","key":"10.1016\/j.canlet.2026.218843_bib37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature00858","article-title":"Release of chromatin protein HMGB1 by necrotic cells triggers inflammation","volume":"418","author":"Scaffidi","year":"2002","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.canlet.2026.218843_bib38","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.canlet.2026.218843_bib39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12601","article-title":"High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair","volume":"280","author":"Bianchi","year":"2017","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.canlet.2026.218843_bib40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s12276-022-00736-w","article-title":"The mechanism of HMGB1 secretion and release","volume":"54","author":"Chen","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.canlet.2026.218843_bib41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s10020-025-01235-0","article-title":"Cytoplasmic HMGB1 promotes the activation of JAK2-STAT3 signaling and PD-L1 expression in breast cancer","volume":"31","author":"Han","year":"2025","journal-title":"Mol. Med."},{"issue":"16","key":"10.1016\/j.canlet.2026.218843_bib42","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1158\/0008-5472.CAN-22-3140","article-title":"Elevated mast cell abundance is associated with enrichment of CCR2+ cytotoxic T cells and favorable prognosis in lung adenocarcinoma","volume":"83","author":"Fan","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218843_bib43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","article-title":"Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.canlet.2026.218843_bib44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-020-01165-x","article-title":"CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis","volume":"19","author":"Yang","year":"2020","journal-title":"Mol. Cancer"},{"issue":"7355","key":"10.1016\/j.canlet.2026.218843_bib45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.canlet.2026.218843_bib46","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/0008-5472.CAN-11-1792","article-title":"Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment","volume":"72","author":"Lesokhin","year":"2012","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2026.218843_bib47","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.celrep.2017.07.027","article-title":"Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells","volume":"20","author":"Okada","year":"2017","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.canlet.2026.218843_bib48","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41467-021-22618-x","article-title":"FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer","volume":"12","author":"Huang","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:19:14Z","timestamp":1791339554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526006075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":48,"alternative-id":["S0304383526006075"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218843","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-cell HMGB1 restrains CD8+ T-cell immunity during conventional fractionated radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218843"}}